Publication details
Ticagrelor ve velkých klinických studiích
| Title in English | Ticagrelor in Large Clinical Trials |
|---|---|
| Authors | |
| Year of publication | 2015 |
| Type | Article in Proceedings |
| Conference | Arteriální hypertenze - současné klinické trendy XIII |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | ticagrelor; myocardial infarction; bleeding |
| Description | Ticagrelor is an oral direct inhibitor of adenosinediphosphate (ADP) type P2Y12 with a quick antiagregation effect and is not a thienopyridine. In a big multicentric trial called PLATO was tested in 18 624 patients with acute coro-nary syndrome with or with ST elevation and has shown a 9,8% versus 11,7% decrease in major cardiovascular event. No difference in bleeding was ob-served. The clinical trial PEGASUS was finished o autumn 2014. 21 162 patients with a history of myocardial infarction were included and randomized on 2 doses of ticagrelor or placebo. All patients were treated with aspirin. The primary endpoint was a combination of death, myocardial infarction or stroke. The primary safety endpoint was bleeding. The results were presented on AHA congress in San Diego in March 2015 and published in NEJM. |